Assoc. Prof. YAĞMUR AKDAĞ ÇAYLI

Publication Network

Articles 26

1. Application of artificial neural network to determine optimum formulation development and in vitro characterization of methylene blue and galantamine loaded polymeric nanoparticles for the treatment of Alzheimer's disease

Ozturk B., Demir Kabaş H., SİLİNDİR GÜNAY M., AKDAĞ ÇAYLI Y., ŞAHİN S., GÜLSÜN İNAL T.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES , vol.216, 2026 (SCI-Expanded, Scopus)

2. Photodynamic and Photothermal Therapies using Nanotechnology Approach in Alzheimer's Disease

Ozturk B., Demir Kabaş H., Gunay M., AKDAĞ ÇAYLI Y., ŞAHİN S., GÜLSÜN İNAL T.

CURRENT NEUROPHARMACOLOGY , vol.23, no.14, pp.1985-2003, 2025 (SCI-Expanded, Scopus) Sustainable Development

3. **Optimization of Glyburide-Loaded Nanosuspensions via Ball Milling and Homogenization Techniques: A Central Composite Design Approach for Enhanced Solubility**

Gungor D., AYTEKİN E., AKDAĞ ÇAYLI Y., ŞAHİN S., GÜLSÜN İNAL T.

CURRENT PHARMACEUTICAL DESIGN , no.5, pp.377-390, 2024 (SCI-Expanded)

4. Electrospun nanofiber drug delivery systems and recent applications: An overview

Muratoglu S., Inal M., AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., ŞAHİN S.

Journal of Drug Delivery Science and Technology , vol.92, 2024 (SCI-Expanded)

5. Antibody Conjugated Nano-Enabled Drug Delivery Systems Against Brain Tumors

Topçu B. T., Bozdağ Pehlivan S., AKDAĞ ÇAYLI Y., Mut M., ÖNER L.

Journal of Pharmaceutical Sciences , 2024 (SCI-Expanded)

6. PHARMA 4.0 APPROACH IN PHARMACEUTICAL INDUSTRY

Bebek G., AKDAG Y., ONER L.

Ankara Üniversitesi Eczacılık Fakültesi Dergisi , vol.47, no.3, pp.1058-1070, 2023 (Scopus)

7. Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation

Arslan A., YET B., NEMUTLU E., AKDAĞ ÇAYLI Y., EROĞLU H., ÖNER L.

Pharmaceutics , vol.15, no.2, 2023 (SCI-Expanded)

8. Nanoparticle-Containing Lyophilized Dry Powder Inhaler Formulations Optimized Using Central Composite Design with Improved Aerodynamic Parameters, and Redispersibility.

Akdag Y.

Pharmaceutical development and technology , vol.28, no.1, pp.124-137, 2023 (SCI-Expanded)

9. Design of Besifloxacin HCl-Loaded Nanostructured Lipid Carriers: In Vitro and Ex Vivo Evaluation

POLAT H. K., Kurt N., AYTEKİN E., AKDAĞ ÇAYLI Y., Pehlivan S., ÇALIŞ S.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS , vol.38, no.6, pp.412-423, 2022 (SCI-Expanded)

10. Formulation and characterization of mometasone furoate and formoterol fumarate containing dry powder inhaler by spray drying and homogenization methods

AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÖNER L., ŞAHİN S.

JOURNAL OF RESEARCH IN PHARMACY , vol.26, no.2, pp.383-396, 2022 (ESCI)

11. The development and characterization of electrospun gelatin nanofibers containing indomethacin and curcumin for accelerated wound healing

Gulsun T., Inal M., Akdag Y., İZAT N., ÖNER L., ŞAHİN S.

Journal of Drug Delivery Science and Technology , vol.67, 2022 (SCI-Expanded)

12. Effects of Surfactants on Albumin Nanoparticles

Akdag Y., Geyik Z. M.

Journal of Research in Pharmacy , vol.26, no.5, pp.1177-1189, 2022 (Scopus)

13. Evaluation of preparation methods for orally disintegrating tablets

AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÇETİN M., ÖNER L., ŞAHİN S.

Medicine Science , vol.9, no.1, pp.259-263, 2020 (Peer-Reviewed Journal)

14. Development and characterization of metformin hydrochloride- and glyburide-containing orally disintegrating tablets

GÜLSÜN İNAL T., AKDAĞ ÇAYLI Y., İZAT N., ÇETİN M., ÖNER L., ŞAHİN S.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY , vol.25, no.8, pp.999-1009, 2020 (SCI-Expanded) Sustainable Development

15. Development of an Anti-Inflammatory Drug-Incorporated Biomimetic Scaffold for Corneal Tissue Engineering

Celebier S. K., Pehlivan S., DEMİRBİLEK M., Akinci M., VURAL İ., AKDAĞ ÇAYLI Y., et al.

Journal of Ocular Pharmacology and Therapeutics , vol.36, no.6, pp.433-446, 2020 (SCI-Expanded)

16. Characterization and comparison of deferasirox fast disintegrating tablets prepared by direct compression and lyophilization methods

AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÇETİN M., ÖNER L., ŞAHİN S.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.57, 2020 (SCI-Expanded)

17. Comparison of Dissolution Profiles and Apparent Permeabilities of Commercially Available Metformin Hydrochloride Tablets in Turkey

AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÖNER L., ŞAHİN S.

DISSOLUTION TECHNOLOGIES , vol.27, no.1, 2020 (SCI-Expanded)

18. Development of dry powder inhaler formulations for drug delivery systems

Akdağ Çaylı Y.

Journal of Research in Pharmacy , vol.23, no.6, pp.1-15, 2019 (Peer-Reviewed Journal)

19. Cyber-physical-based PAT (CPbPAT) framework for Pharma 4.0

Barenji R. V., Akdag Y., YET B., ÖNER L.

INTERNATIONAL JOURNAL OF PHARMACEUTICS , vol.567, 2019 (SCI-Expanded) Sustainable Development

20. Effect of particle size and surfactant on the solubility, permeability and dissolution characteristics of deferasirox

Gulsun T., Akdag Y., İZAT N., ÖNER L., ŞAHİN S.

Journal of Research in Pharmacy , vol.23, no.5, pp.851-859, 2019 (SSCI)

21. Determination of N-acetylcysteine in the presence of ciprofloxacin or levofloxacin in microparticulate dry powder inhalers

Akdag Y., ŞAHİN S., NEMUTLU E., ÖNER L.

TURKISH JOURNAL OF CHEMISTRY , vol.43, no.3, pp.846-856, 2019 (SCI-Expanded)

22. Development of dry powder inhaler formulations for drug delivery systems

AKDAĞ ÇAYLI Y.

JOURNAL OF RESEARCH IN PHARMACY , vol.23, no.6, pp.973-987, 2019 (ESCI)

23. Development and evaluation of terbutaline sulfate orally disintegrating tablets by direct compression and freeze drying methods

Gulsun T., Cayli Y., İZAT N., ÇETİN M., ÖNER L., ŞAHİN S.

Journal of Drug Delivery Science and Technology , vol.46, pp.251-258, 2018 (SCI-Expanded)

24. Dry Powder Inhalers: Formulations and Aerodynamic Behaviours

AKDAĞ ÇAYLI Y., ŞAHİN S., ÖNER L.

Hacettepe University Journal of the Faculty of Pharmacy , vol.38, no.1, pp.39-52, 2018 (Scopus)

25. Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.

Akdag C., SAHIN S., BUTTINI F., BALDUCCI A., MONTANARI S., VURAL I., et al.

Drug development and industrial pharmacy , vol.43, pp.1378-1389, 2017 (SCI-Expanded)

26. Preparation and in vitro/in vivo evaluation of rofecoxib containing bovine serum albumin microspheres

Demirturk E., Gulsun T., Cayli Y., İZAT N., ŞAHİN S., ÖNER L.

Latin American Journal of Pharmacy , vol.36, no.6, pp.1096-1104, 2017 (SCI-Expanded)

Papers Presented at Peer-Reviewed Scientific Conferences 39

1. Dry Powder Inhaler Formulations Containing Gefitinib Nanoparticles

Geyik Z. M., Nacak B., Bilal M. N., Gülsün İnal T., Şahin S., Öner L., et al.

9th BBBB International Conference on Pharmaceutical Sciences 2022, Ljubljana, Slovenia, 15 - 17 September 2022, pp.178-179, (Summary Text)

2. Development of besifloxacin loaded nanostructured lipid carrier and characterization studies

Kurt N., Polat H. K., Aytekin E., Akdağ Çaylı Y., Pehlivan S., Çalış S.

20th International Pharmaceutical Technology Symposium - IPTS 2022, 21 - 23 February 2022, pp.1-2, (Full Text)

3. Effects of spray drying and lyophilization methods on aerodynamic parameters in dry powder inhalers

Akdağ Çaylı Y.

20th International Pharmaceutical Technology Symposium - IPTS 2022, Ankara, Turkey, 21 - 23 February 2022, pp.1-2, (Full Text)

4. Gefitinib-human serum albumin nanoparticles production by nanoparticle-albumin bound (NAB™) technology

Geyik Z. M., Nacak B., Bilal M. N., Gülsün İnal T., Şahin S., Öner L., et al.

20th International Pharmaceutical Technology Symposium - IPTS 2022, 21 - 23 February 2022, pp.1-2, (Full Text)

5. Effects of modifications in methyl cellulose nanoparticle production methods on particle size distribution

Taş B., Akdağ Çaylı Y., Pehlivan S., Aytekin E., Çopur T., Sağlam O., et al.

20th International Pharmaceutical Technology Symposium - IPTS 2022, 21 - 23 February 2022, pp.1-2, (Full Text)

6. Validation of an HPLC method for the determination of talazoparib from nanoparticle formulations

Taş B., Akdağ Çaylı Y., Aytekin E., Pehlivan S., Öner L., Kaplan O.

3rd International Gazi Pharma Symposium Series (GPSS-2021), 8 - 10 September 2021, pp.1-2, (Summary Text)

7. Effects of Production Method Variations on Particle Size Distribution of Ethyl Cellulose Nanoparticles

Taş B., Akdağ Çaylı Y., Aytekin E., Pehlivan S., Öner L.

13th International Symposium on Pharmaceutical Sciences (ISOPS), 22 - 25 June 2021, pp.1-2, (Full Text)

8. HUMAN SERUM ALBUMIN NANOPARTICLES FOR TARGETED CANCER THERAPY

AKDAĞ ÇAYLI Y., GEYİK Z. M.

13th International Symposium on Pharmaceutical Sciences (ISOPS), 22 - 25 June 2021, (Full Text) Sustainable Development

9. Effects of Preparation Methods on Orally Disintegrating Tablets

AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÇETİN M., ÖNER L., ŞAHİN S.

International Multidisciplinary Symposium on Drug Research Development (DRD 2019), 1 - 03 July 2019, (Full Text)

10. Ağız yolu ile uygulanan etkin maddelerin çözünürlük ve permeabilite özelliklerini arttırmak amacıyla formülasyon geliştirme sürecinde kullanılan yöntemler

AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ŞAHİN S., ÖNER L.

2. Ulusal Marmara Eczacılık Kongresi (UMEK-2), Turkey, 14 - 16 November 2018, (Summary Text)

11. OPTIMIZATION OF NANOSYSTEMS CONTAINING ALBUMIN LINKED PACLITAXEL

AKDAĞ ÇAYLI Y., MURAT Z., EROĞLU H., ÖNER L.

19th International Pharmaceutical Technology Symposium, 17 - 19 September 2018, (Full Text)

12. Investigation of deferasirox permeability from lyophilized orally disintegrating tablet

GÜLSÜN İNAL T., İZAT N., AKDAĞ ÇAYLI Y., ÖNER L., ŞAHİN S.

2017 AAPS Annual Meeting and Exposition, 12 - 15 November 2017, (Summary Text)

13. Investigation of terbutaline sulfate permeability from orally disintegrating tablets

İZAT N., AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., ÖNER L., ŞAHİN S.

2017 AAPS Annual Meeting and Exposition, 12 - 15 November 2017, (Summary Text)

14. Development and Characterization of Indomethacin and Curcumin Containing Nanofibers

İNAL M., GÜLSÜN İNAL T., İZAT N., AKDAĞ ÇAYLI Y., ÖNER L., ŞAHİN S.

GPSS 2017, 11 - 13 October 2017, (Summary Text)

15. Development and Evaluation of Lyophilized Orally Disintegrating Tablets Containing Metformin Hydrochloride and Glyburide

AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÇETİN M., ÖNER L., ŞAHİN S.

77th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2017, 10 - 14 September 2017, (Summary Text)

16. Antibiyotik İçeren Kuru Toz İnhaler Formülasyonları

AKDAĞ ÇAYLI Y., ŞAHİN S., ÖNER L.

1. Anadolu Üniversitesi Eczacılık Fakültesi Sempozyumu (ANES), Turkey, 1 - 02 June 2017, (Summary Text)

17. Development and Validation of an HPLC method for Simultaneous Determination of Ciprofloxacin Levofloxacin and N acetylcysteine

AKDAĞ ÇAYLI Y., ŞAHİN S., VURAL İ., ÖNER L.

2016 AAPS Annual Meeting and Exposition, 13 - 17 November 2016, (Summary Text)

22. Formulation and Characterization of Mometasone Furoate Monohydrate and Formoterol Fumarate Dihydrate Containing Dry Powder Inhaler Formulations

AKDAĞ ÇAYLI Y., GÜLSÜN İNAL T., İZAT N., ÖNER L., ŞAHİN S.

2016 AAPS Annual Meeting and Exposition, 13 - 17 November 2016, (Summary Text)

Metrics

Publication

Publication (WoS)

Publication (Scopus)

Citation (WoS)

151

H-Index (WoS)

Citation (Scopus)

136

H-Index (Scopus)

Project

Open Access

UN Sustainable Development Goals

Publications & Works

Publication

Publication (WoS)

Publication (Scopus)

Citation (WoS)

H-Index (WoS)

Citation (Scopus)

H-Index (Scopus)

Project

Open Access